Resiliency Training in Adolescents With NF1 and NF2
- Conditions
- Neurofibromatoses
- Interventions
- Behavioral: Stress and Symptom Management Program 1Behavioral: Stress and Symptom Management Program 2
- Registration Number
- NCT03873610
- Lead Sponsor
- Massachusetts General Hospital
- Brief Summary
This randomized controlled trial for resiliency training in adolescents with Neurofibromatosis 1 and Neurofibromatosis 2 via secure live video to determine the efficacy two stress and symptom management programs. Both programs are 8 week group programs.
- Detailed Description
Neurofibromatosis (NFs) are rare genetic conditions with cure. Adolescents with NF experience more symptoms of depression and anxiety, higher levels of stress associated with coping with NF symptoms, lower levels of self esteem, difficulties with social skills and social support, high rates of learning disabilities, and more pain as compared with the general population norms.
The aims of this study are to compare the effect of two stress and symptom management programs tailored for adolescents with neurofibromatosis on quality of life and psychosocial functioning. We will also examine the degree to which treatment-dependent improvements in quality of life are mediated by improvements in depression, pain intensity and pain interference.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 200
- Has a diagnosis of NF1 or NF2 and is between the ages of 12-17
- Is capable of completing and fully understanding the informed consent process/assent and the study procedures and assessments in English; has parental approval for participation
- English speaking and at least a 3rd grade self-reported and parent reported reading level
- Self reported/parent reported difficulties coping with stress and NF symptoms
- Has major medical co-morbidity not NF related expected to worsen in the next 12 months
- Recent (within past 3 months) change in antidepressant medication
- Recent participation in cognitive behavioral therapy or relaxation therapy (within past 3 months)
- Has significant mental health diagnosis requiring immediate treatment (e.g., untreated bipolar disorder, psychotic disorder, active substance dependence)
- Unable or unwilling to complete assessments electronically via REDCap
- Unable or unwilling to participate in group videoconferencing sessions
- Unable or unwilling to participate along with at least 1 parent in a video screening session
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Stress and Symptom Management Program 1 Stress and Symptom Management Program 1 - Stress and Symptom Management 2 Stress and Symptom Management Program 2 -
- Primary Outcome Measures
Name Time Method Change in Physical Health Quality of Life 0 weeks, 8 weeks, 6 months,12 months World Health Organization Quality of Life Brief (WHOQOL-BREF); 4-20; Higher score indicates higher QoL
Change in Psychological Health Quality of Life 0 weeks, 8 weeks, 6 months,12 months World Health Organization Quality of Life Brief (WHOQOL-BREF); 4-20; Higher score indicates higher QoL
- Secondary Outcome Measures
Name Time Method Social relationships Quality of Life 0 weeks, 8 weeks, 6 months,12 months World Health Organization Quality of Life Brief (WHOQOL-BREF); 4-20; Higher score indicates higher QoL
Environmental Quality of Life 0 weeks, 8 weeks, 6 months, 12 months World Health Organization Quality of Life Brief (WHOQOL-BREF); 4-20; Higher score indicates higher QoL
Depression 0 weeks, 8 weeks, 6 months, 12 months Patient Health Questionnaire (PHQ-9) Adolescent Version; 0-27; Higher score indicates more symptoms of depression
Anxiety 0 weeks, 8 weeks, 6 months, 12 months Generalized Anxiety Disorder (GAD-7) Questionnaire; 0-21; Higher score indicates more symptoms of anxiety
Pain intensity 0 weeks, 8 weeks, 6 months, 12 months Numerical Rating Scale; 0-10; Higher score indicates more intense pain.
Pain interference 0 weeks, 8 weeks, 6 months, 12 months Pain Interference Index (PII); 0-36; Higher score indicates more pain interference
Trial Locations
- Locations (1)
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States